Integrative analysis of m6A-SNPs and single-cell RNA sequencing reveals key drivers of endocrine combined with CDK4/6 inhibitor therapy resistance in ER+ breast cancer
Our findings emphasize the importance of m6A-SNPs in influencing resistance to therapy in ER+ breast cancer. The dynamic regulation of FILIP1L and TOM1L1 along the developmental trajectory of tumor cells from sensitivity to resistance provides insights into the molecular complexity of therapy resistance. These results pave the way for developing targeted therapies that modify m6A-driven pathways, offering new strategies to counteract resistance and improve patient outcomes.
Authors
- Xiaoping Huang (ORCID: https://orcid.org/0000-0002-0332-1999)
- Fangbiao Zhan (ORCID: https://orcid.org/0000-0001-6965-7404)
- Huawen Liu (ORCID: https://orcid.org/0000-0003-1185-6958)
- Ruijie Ming
- Han Zhang (ORCID: https://orcid.org/0000-0001-9522-4418)
- Huan Wu (ORCID: https://orcid.org/0000-0002-8689-0379)
Institutions
- Chongqing University (CN)
- Chongqing Three Gorges University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-15
- DOI
- https://doi.org/10.3389/fphar.2025.1590363
- Citations
- 1
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Chongqing University